| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large-Cell, Anaplastic | 57 | 2024 | 388 | 12.870 |
Why?
|
| Breast Implants | 49 | 2024 | 376 | 11.250 |
Why?
|
| Craving | 11 | 2022 | 43 | 6.330 |
Why?
|
| Breast Implantation | 26 | 2024 | 222 | 5.100 |
Why?
|
| Alcoholism | 18 | 2021 | 330 | 4.290 |
Why?
|
| Alcohol Drinking | 18 | 2024 | 600 | 3.810 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 41 | 2024 | 1737 | 3.790 |
Why?
|
| Marijuana Abuse | 7 | 2021 | 67 | 2.970 |
Why?
|
| Cues | 8 | 2020 | 200 | 2.630 |
Why?
|
| Epstein-Barr Virus Infections | 15 | 2024 | 475 | 2.290 |
Why?
|
| Lymphoma, B-Cell | 17 | 2023 | 936 | 2.020 |
Why?
|
| Fructose | 5 | 2018 | 70 | 1.920 |
Why?
|
| Splenic Neoplasms | 10 | 2018 | 125 | 1.870 |
Why?
|
| Immunophenotyping | 33 | 2024 | 1732 | 1.790 |
Why?
|
| Ecological Momentary Assessment | 6 | 2024 | 21 | 1.790 |
Why?
|
| Breast Neoplasms | 39 | 2024 | 16241 | 1.750 |
Why?
|
| Lymphoma, Mantle-Cell | 15 | 2023 | 749 | 1.530 |
Why?
|
| Lymphoma, T-Cell | 8 | 2018 | 369 | 1.500 |
Why?
|
| Underage Drinking | 2 | 2021 | 11 | 1.420 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 9 | 2023 | 191 | 1.410 |
Why?
|
| Humans | 299 | 2024 | 271884 | 1.400 |
Why?
|
| Leukemia, Large Granular Lymphocytic | 6 | 2018 | 67 | 1.340 |
Why?
|
| Young Adult | 67 | 2024 | 22108 | 1.340 |
Why?
|
| Hodgkin Disease | 11 | 2024 | 1488 | 1.330 |
Why?
|
| Adult | 154 | 2024 | 81857 | 1.310 |
Why?
|
| Peer Group | 4 | 2021 | 135 | 1.290 |
Why?
|
| Female | 200 | 2024 | 149143 | 1.270 |
Why?
|
| Immunohistochemistry | 50 | 2024 | 7822 | 1.230 |
Why?
|
| Motivational Interviewing | 2 | 2021 | 47 | 1.230 |
Why?
|
| Mastocytosis, Systemic | 5 | 2024 | 119 | 1.200 |
Why?
|
| Bone Marrow | 22 | 2022 | 2435 | 1.190 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 6 | 2021 | 303 | 1.140 |
Why?
|
| Receptors, Antigen, T-Cell, gamma-delta | 9 | 2021 | 172 | 1.110 |
Why?
|
| Middle Aged | 151 | 2024 | 90395 | 1.100 |
Why?
|
| Skin Neoplasms | 16 | 2024 | 4889 | 1.100 |
Why?
|
| Naltrexone | 6 | 2018 | 99 | 1.090 |
Why?
|
| B-Lymphocytes | 8 | 2024 | 1429 | 1.080 |
Why?
|
| Castleman Disease | 4 | 2019 | 72 | 1.060 |
Why?
|
| Male | 164 | 2024 | 128957 | 1.040 |
Why?
|
| Mast Cells | 5 | 2024 | 231 | 1.020 |
Why?
|
| Hematologic Neoplasms | 12 | 2024 | 1950 | 1.020 |
Why?
|
| Self Report | 2 | 2020 | 796 | 1.010 |
Why?
|
| Aged | 131 | 2024 | 73471 | 1.010 |
Why?
|
| Gene Rearrangement | 18 | 2023 | 817 | 1.000 |
Why?
|
| Adolescent | 58 | 2024 | 32663 | 1.000 |
Why?
|
| Biomarkers, Tumor | 38 | 2023 | 10750 | 0.980 |
Why?
|
| Alcohol-Related Disorders | 3 | 2014 | 43 | 0.970 |
Why?
|
| Ki-1 Antigen | 10 | 2023 | 186 | 0.950 |
Why?
|
| Herpesvirus 4, Human | 11 | 2024 | 954 | 0.940 |
Why?
|
| Adolescent Behavior | 3 | 2018 | 239 | 0.940 |
Why?
|
| Proto-Oncogene Proteins c-myc | 13 | 2023 | 845 | 0.930 |
Why?
|
| Anticonvulsants | 3 | 2018 | 445 | 0.920 |
Why?
|
| In Situ Hybridization, Fluorescence | 22 | 2023 | 2317 | 0.920 |
Why?
|
| World Health Organization | 4 | 2024 | 328 | 0.920 |
Why?
|
| Myelodysplastic Syndromes | 10 | 2019 | 3148 | 0.920 |
Why?
|
| Lymphoproliferative Disorders | 5 | 2020 | 382 | 0.890 |
Why?
|
| Receptors, Dopamine D4 | 4 | 2018 | 9 | 0.850 |
Why?
|
| Iatrogenic Disease | 2 | 2013 | 197 | 0.830 |
Why?
|
| Genes, myc | 6 | 2017 | 375 | 0.820 |
Why?
|
| Affect | 3 | 2022 | 306 | 0.800 |
Why?
|
| CD5 Antigens | 4 | 2015 | 130 | 0.770 |
Why?
|
| Sexual and Gender Minorities | 1 | 2022 | 76 | 0.770 |
Why?
|
| Histiocytic Necrotizing Lymphadenitis | 2 | 2020 | 9 | 0.760 |
Why?
|
| Diagnosis, Differential | 32 | 2024 | 4891 | 0.750 |
Why?
|
| Alcohol Drinking in College | 1 | 2020 | 9 | 0.710 |
Why?
|
| Cannabis | 1 | 2021 | 70 | 0.710 |
Why?
|
| Lymphoma, Primary Effusion | 1 | 2020 | 13 | 0.700 |
Why?
|
| Killer Cells, Natural | 2 | 2024 | 966 | 0.700 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 8 | 2020 | 331 | 0.690 |
Why?
|
| Varenicline | 1 | 2020 | 72 | 0.680 |
Why?
|
| Nicotinic Agonists | 2 | 2020 | 121 | 0.680 |
Why?
|
| Memory, Short-Term | 1 | 2021 | 161 | 0.680 |
Why?
|
| Skin Abnormalities | 1 | 2019 | 32 | 0.670 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2019 | 36 | 0.670 |
Why?
|
| Aged, 80 and over | 62 | 2024 | 31042 | 0.670 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2020 | 154 | 0.660 |
Why?
|
| Mental Recall | 1 | 2020 | 173 | 0.650 |
Why?
|
| Prognosis | 48 | 2024 | 22537 | 0.650 |
Why?
|
| Opioid-Related Disorders | 1 | 2024 | 415 | 0.640 |
Why?
|
| Flow Cytometry | 14 | 2024 | 3078 | 0.640 |
Why?
|
| Lymphoma, Follicular | 7 | 2023 | 636 | 0.630 |
Why?
|
| Risk-Taking | 1 | 2019 | 131 | 0.630 |
Why?
|
| Chromosomes, Human, Pair 8 | 5 | 2017 | 330 | 0.630 |
Why?
|
| Appetitive Behavior | 1 | 2018 | 20 | 0.620 |
Why?
|
| Bone Marrow Neoplasms | 2 | 2018 | 128 | 0.620 |
Why?
|
| Receptors, Opioid, mu | 4 | 2012 | 96 | 0.620 |
Why?
|
| Intestinal Diseases | 1 | 2019 | 126 | 0.620 |
Why?
|
| Sex Characteristics | 1 | 2021 | 434 | 0.620 |
Why?
|
| Reflex, Startle | 1 | 2018 | 66 | 0.610 |
Why?
|
| Blinking | 1 | 2018 | 43 | 0.610 |
Why?
|
| Monitoring, Ambulatory | 1 | 2018 | 61 | 0.590 |
Why?
|
| Lymph Nodes | 14 | 2024 | 3080 | 0.590 |
Why?
|
| Interleukin-6 | 2 | 2019 | 1066 | 0.580 |
Why?
|
| Data Collection | 1 | 2020 | 624 | 0.580 |
Why?
|
| Rituximab | 17 | 2024 | 1588 | 0.570 |
Why?
|
| Social Environment | 1 | 2018 | 181 | 0.560 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2023 | 685 | 0.560 |
Why?
|
| Mycosis Fungoides | 4 | 2024 | 335 | 0.560 |
Why?
|
| Vascular Diseases | 1 | 2019 | 243 | 0.560 |
Why?
|
| Double-Blind Method | 8 | 2020 | 2619 | 0.560 |
Why?
|
| Leukemia, B-Cell | 2 | 2014 | 114 | 0.560 |
Why?
|
| Treatment Outcome | 40 | 2021 | 33863 | 0.550 |
Why?
|
| Retroperitoneal Neoplasms | 1 | 2019 | 299 | 0.550 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2023 | 1547 | 0.550 |
Why?
|
| Eosinophilia | 2 | 2015 | 188 | 0.540 |
Why?
|
| Immune System Diseases | 1 | 2016 | 65 | 0.530 |
Why?
|
| Myeloproliferative Disorders | 5 | 2018 | 881 | 0.530 |
Why?
|
| Combined Modality Therapy | 17 | 2023 | 9044 | 0.520 |
Why?
|
| Mammaplasty | 5 | 2022 | 715 | 0.520 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 3 | 2018 | 461 | 0.510 |
Why?
|
| Genes, bcl-2 | 2 | 2014 | 174 | 0.510 |
Why?
|
| Biopsy | 19 | 2022 | 3544 | 0.510 |
Why?
|
| Psychotherapy | 1 | 2018 | 246 | 0.510 |
Why?
|
| Diarrhea | 1 | 2019 | 730 | 0.510 |
Why?
|
| Ethanol | 7 | 2022 | 269 | 0.510 |
Why?
|
| Immunologic Deficiency Syndromes | 2 | 2018 | 255 | 0.510 |
Why?
|
| Device Removal | 6 | 2021 | 338 | 0.510 |
Why?
|
| Peritoneal Diseases | 2 | 2010 | 33 | 0.500 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2015 | 130 | 0.480 |
Why?
|
| Neoplasms, Second Primary | 4 | 2022 | 1388 | 0.480 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 36 | 2024 | 16610 | 0.480 |
Why?
|
| Spiritual Therapies | 1 | 2014 | 5 | 0.470 |
Why?
|
| Lymphoma | 7 | 2022 | 1514 | 0.470 |
Why?
|
| Translocation, Genetic | 8 | 2017 | 1288 | 0.470 |
Why?
|
| Neuroprotective Agents | 1 | 2016 | 218 | 0.450 |
Why?
|
| Medication Adherence | 2 | 2018 | 519 | 0.450 |
Why?
|
| Karyotyping | 7 | 2024 | 1064 | 0.440 |
Why?
|
| Cyclin D1 | 5 | 2023 | 594 | 0.440 |
Why?
|
| Oncogene Proteins, Fusion | 5 | 2024 | 802 | 0.440 |
Why?
|
| Skin Diseases | 3 | 2022 | 366 | 0.440 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2013 | 34 | 0.440 |
Why?
|
| Mutation | 20 | 2024 | 15924 | 0.430 |
Why?
|
| Blast Crisis | 3 | 2016 | 587 | 0.430 |
Why?
|
| Leukemia, Hairy Cell | 3 | 2014 | 129 | 0.430 |
Why?
|
| Thrombocytopenia | 2 | 2015 | 872 | 0.430 |
Why?
|
| Protein-Tyrosine Kinases | 4 | 2016 | 1842 | 0.430 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 720 | 0.430 |
Why?
|
| Waldenstrom Macroglobulinemia | 4 | 2020 | 285 | 0.430 |
Why?
|
| Spirituality | 1 | 2014 | 129 | 0.420 |
Why?
|
| Salivary Gland Diseases | 2 | 2003 | 11 | 0.420 |
Why?
|
| Tobacco Use Disorder | 2 | 2021 | 297 | 0.410 |
Why?
|
| Predictive Value of Tests | 12 | 2024 | 4998 | 0.400 |
Why?
|
| Lymphadenopathy | 3 | 2022 | 94 | 0.400 |
Why?
|
| Cytogenetic Analysis | 5 | 2019 | 574 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 10 | 2024 | 7246 | 0.400 |
Why?
|
| CD8-Positive T-Lymphocytes | 4 | 2021 | 1657 | 0.400 |
Why?
|
| Gene-Environment Interaction | 1 | 2012 | 163 | 0.390 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 6 | 2020 | 2634 | 0.390 |
Why?
|
| Germinal Center | 5 | 2017 | 168 | 0.390 |
Why?
|
| Antisocial Personality Disorder | 2 | 2009 | 65 | 0.390 |
Why?
|
| Smoking Cessation | 3 | 2021 | 768 | 0.390 |
Why?
|
| Peritoneal Neoplasms | 4 | 2022 | 856 | 0.380 |
Why?
|
| Neutropenia | 1 | 2015 | 1001 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-kit | 4 | 2016 | 490 | 0.380 |
Why?
|
| Chromosome Deletion | 4 | 2015 | 1055 | 0.380 |
Why?
|
| Burkitt Lymphoma | 4 | 2021 | 350 | 0.370 |
Why?
|
| Vincristine | 16 | 2024 | 1572 | 0.370 |
Why?
|
| Acquired Immunodeficiency Syndrome | 2 | 2003 | 370 | 0.370 |
Why?
|
| Surface Properties | 5 | 2021 | 188 | 0.360 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2019 | 1068 | 0.360 |
Why?
|
| Prednisone | 14 | 2024 | 1036 | 0.360 |
Why?
|
| Histiocytosis, Langerhans-Cell | 3 | 2022 | 284 | 0.360 |
Why?
|
| Immunosuppressive Agents | 2 | 2014 | 1442 | 0.350 |
Why?
|
| T-Lymphocytes | 7 | 2024 | 3947 | 0.350 |
Why?
|
| Leukemia | 4 | 2022 | 1721 | 0.350 |
Why?
|
| Liver Neoplasms | 7 | 2018 | 4809 | 0.340 |
Why?
|
| Chromosome Aberrations | 7 | 2024 | 2034 | 0.340 |
Why?
|
| Arthritis, Rheumatoid | 2 | 2015 | 498 | 0.340 |
Why?
|
| Ascites | 1 | 2010 | 216 | 0.340 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 433 | 0.340 |
Why?
|
| Time Factors | 16 | 2022 | 13130 | 0.340 |
Why?
|
| Disease Management | 7 | 2024 | 1111 | 0.340 |
Why?
|
| Antigens, CD | 6 | 2019 | 1436 | 0.330 |
Why?
|
| Substance-Related Disorders | 2 | 2014 | 550 | 0.330 |
Why?
|
| Specimen Handling | 2 | 2023 | 314 | 0.330 |
Why?
|
| Janus Kinase 2 | 3 | 2018 | 754 | 0.330 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2009 | 68 | 0.320 |
Why?
|
| Human T-lymphotropic virus 1 | 2 | 2022 | 103 | 0.320 |
Why?
|
| Hyalin | 2 | 2019 | 18 | 0.320 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2020 | 879 | 0.320 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2016 | 6270 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2010 | 413 | 0.320 |
Why?
|
| Parenting | 1 | 2012 | 353 | 0.310 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2010 | 205 | 0.310 |
Why?
|
| Neoplasm Proteins | 5 | 2018 | 3363 | 0.310 |
Why?
|
| Tumor Suppressor Protein p53 | 8 | 2024 | 3670 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1053 | 0.300 |
Why?
|
| Doxorubicin | 16 | 2024 | 3131 | 0.300 |
Why?
|
| Lymphomatoid Papulosis | 2 | 2021 | 67 | 0.300 |
Why?
|
| Narcotic Antagonists | 4 | 2018 | 154 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 2018 | 296 | 0.290 |
Why?
|
| Cyclophosphamide | 16 | 2024 | 3231 | 0.290 |
Why?
|
| Hepacivirus | 3 | 2020 | 423 | 0.290 |
Why?
|
| Neoplasms, Connective Tissue | 1 | 2007 | 20 | 0.280 |
Why?
|
| Behavior, Addictive | 1 | 2008 | 105 | 0.280 |
Why?
|
| Thiazoles | 1 | 2011 | 725 | 0.280 |
Why?
|
| Hematopoiesis, Extramedullary | 1 | 2006 | 44 | 0.280 |
Why?
|
| Sarcoma, Clear Cell | 1 | 2007 | 43 | 0.280 |
Why?
|
| Histiocytes | 4 | 2020 | 95 | 0.280 |
Why?
|
| Chorioamnionitis | 1 | 2006 | 42 | 0.270 |
Why?
|
| Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 3 | 2012 | 41 | 0.270 |
Why?
|
| Prosthesis Design | 4 | 2021 | 663 | 0.270 |
Why?
|
| Lymphoid Tissue | 2 | 2024 | 103 | 0.270 |
Why?
|
| Plasmablastic Lymphoma | 2 | 2017 | 37 | 0.270 |
Why?
|
| Sarcoma, Kaposi | 2 | 2011 | 192 | 0.270 |
Why?
|
| Stillbirth | 1 | 2006 | 86 | 0.270 |
Why?
|
| HIV Infections | 4 | 2015 | 2157 | 0.260 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 9 | 2016 | 879 | 0.260 |
Why?
|
| Risk Factors | 14 | 2024 | 18045 | 0.260 |
Why?
|
| Neoplasm Staging | 16 | 2021 | 13993 | 0.260 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 2 | 2017 | 48 | 0.260 |
Why?
|
| Papillomaviridae | 1 | 2009 | 645 | 0.260 |
Why?
|
| Postoperative Complications | 6 | 2024 | 5690 | 0.260 |
Why?
|
| Dendritic Cells | 4 | 2021 | 1112 | 0.260 |
Why?
|
| Phenotype | 10 | 2021 | 6515 | 0.260 |
Why?
|
| Retrospective Studies | 29 | 2021 | 39780 | 0.250 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2022 | 10365 | 0.250 |
Why?
|
| Stem Cell Transplantation | 5 | 2021 | 1423 | 0.250 |
Why?
|
| Neoplasms, Multiple Primary | 3 | 2020 | 564 | 0.250 |
Why?
|
| Photic Stimulation | 2 | 2018 | 273 | 0.240 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2020 | 2474 | 0.240 |
Why?
|
| T-Lymphocytes, Regulatory | 3 | 2015 | 716 | 0.240 |
Why?
|
| Antigens, Nuclear | 1 | 2005 | 128 | 0.240 |
Why?
|
| Herpesvirus 8, Human | 3 | 2020 | 108 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2016 | 4964 | 0.240 |
Why?
|
| Arteriosclerosis | 1 | 2005 | 185 | 0.240 |
Why?
|
| Survival Rate | 17 | 2020 | 12533 | 0.240 |
Why?
|
| Breast | 5 | 2021 | 1380 | 0.240 |
Why?
|
| Antibodies, Monoclonal | 2 | 2017 | 4495 | 0.240 |
Why?
|
| Plasma Cells | 3 | 2020 | 201 | 0.230 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 1 | 3 | 2017 | 189 | 0.230 |
Why?
|
| Dura Mater | 2 | 2013 | 77 | 0.230 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2017 | 2624 | 0.230 |
Why?
|
| Polymerase Chain Reaction | 6 | 2017 | 3512 | 0.230 |
Why?
|
| Disease-Free Survival | 11 | 2017 | 10259 | 0.230 |
Why?
|
| Opiate Substitution Treatment | 1 | 2024 | 32 | 0.230 |
Why?
|
| Longitudinal Studies | 2 | 2020 | 2053 | 0.230 |
Why?
|
| Transcriptome | 7 | 2021 | 1948 | 0.230 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 2020 | 1143 | 0.230 |
Why?
|
| Bone Marrow Diseases | 2 | 2015 | 187 | 0.220 |
Why?
|
| Cell Lineage | 2 | 2019 | 706 | 0.220 |
Why?
|
| Emotions | 2 | 2018 | 556 | 0.220 |
Why?
|
| Hepatitis C | 2 | 2020 | 551 | 0.220 |
Why?
|
| Monocytes | 2 | 2005 | 789 | 0.220 |
Why?
|
| Positron-Emission Tomography | 3 | 2019 | 2198 | 0.220 |
Why?
|
| Angiomatosis, Bacillary | 1 | 2002 | 9 | 0.220 |
Why?
|
| Dermatitis Herpetiformis | 1 | 2022 | 7 | 0.220 |
Why?
|
| Lymphocyte Count | 3 | 2015 | 485 | 0.210 |
Why?
|
| Friends | 2 | 2021 | 25 | 0.210 |
Why?
|
| Collagen Type I | 1 | 2003 | 191 | 0.210 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2022 | 72 | 0.210 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 2 | 2021 | 263 | 0.210 |
Why?
|
| Child | 23 | 2021 | 30492 | 0.210 |
Why?
|
| Asbestos | 1 | 2022 | 37 | 0.210 |
Why?
|
| Environment | 3 | 2013 | 176 | 0.210 |
Why?
|
| Sjogren's Syndrome | 1 | 2003 | 105 | 0.200 |
Why?
|
| Delay Discounting | 1 | 2022 | 8 | 0.200 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2018 | 1014 | 0.200 |
Why?
|
| Bone Marrow Cells | 5 | 2016 | 983 | 0.200 |
Why?
|
| Nicotine | 2 | 2022 | 266 | 0.200 |
Why?
|
| Economics, Behavioral | 1 | 2022 | 9 | 0.200 |
Why?
|
| Pregnancy Complications, Infectious | 1 | 2006 | 432 | 0.200 |
Why?
|
| SOXC Transcription Factors | 2 | 2023 | 58 | 0.200 |
Why?
|
| Carcinoma, Small Cell | 1 | 2004 | 427 | 0.200 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 2 | 2020 | 105 | 0.200 |
Why?
|
| Alcoholic Intoxication | 2 | 2020 | 13 | 0.200 |
Why?
|
| Biomarkers | 8 | 2022 | 5112 | 0.200 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 190 | 0.200 |
Why?
|
| Follow-Up Studies | 11 | 2022 | 15267 | 0.190 |
Why?
|
| Decision Making | 1 | 2009 | 1243 | 0.190 |
Why?
|
| Age Factors | 7 | 2020 | 5520 | 0.190 |
Why?
|
| Exercise Therapy | 2 | 2015 | 292 | 0.190 |
Why?
|
| Granuloma | 1 | 2022 | 159 | 0.190 |
Why?
|
| Sequence Deletion | 3 | 2022 | 915 | 0.190 |
Why?
|
| CD3 Complex | 2 | 2020 | 321 | 0.190 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2015 | 541 | 0.190 |
Why?
|
| Tonsillar Neoplasms | 1 | 2021 | 81 | 0.190 |
Why?
|
| Aorta | 1 | 2005 | 683 | 0.190 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 3 | 2016 | 186 | 0.190 |
Why?
|
| Pyrimidines | 3 | 2020 | 3664 | 0.190 |
Why?
|
| Seroma | 2 | 2020 | 78 | 0.190 |
Why?
|
| Case-Control Studies | 6 | 2020 | 6236 | 0.190 |
Why?
|
| Disease Progression | 11 | 2021 | 6909 | 0.190 |
Why?
|
| Histiocytosis, Sinus | 1 | 2022 | 87 | 0.190 |
Why?
|
| Scholarly Communication | 1 | 2020 | 19 | 0.180 |
Why?
|
| DNA, Neoplasm | 4 | 2016 | 1972 | 0.180 |
Why?
|
| Child, Preschool | 14 | 2021 | 16999 | 0.180 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 1014 | 0.180 |
Why?
|
| Risk Assessment | 10 | 2024 | 6883 | 0.180 |
Why?
|
| Lymphocytosis | 1 | 2000 | 58 | 0.180 |
Why?
|
| HIV-1 | 2 | 2017 | 641 | 0.180 |
Why?
|
| STAT Transcription Factors | 2 | 2022 | 80 | 0.180 |
Why?
|
| Stromal Cells | 1 | 2024 | 835 | 0.180 |
Why?
|
| Liver | 3 | 2018 | 3123 | 0.180 |
Why?
|
| GATA3 Transcription Factor | 1 | 2021 | 145 | 0.180 |
Why?
|
| High-Throughput Nucleotide Sequencing | 5 | 2024 | 2352 | 0.180 |
Why?
|
| Immunoglobulin Heavy Chains | 2 | 2012 | 242 | 0.180 |
Why?
|
| Antigens, CD7 | 1 | 2020 | 30 | 0.170 |
Why?
|
| Epigenesis, Genetic | 2 | 2019 | 1439 | 0.170 |
Why?
|
| Reed-Sternberg Cells | 2 | 2024 | 46 | 0.170 |
Why?
|
| Pathologists | 1 | 2020 | 102 | 0.170 |
Why?
|
| Leukemia, Erythroblastic, Acute | 2 | 2010 | 123 | 0.170 |
Why?
|
| DNA Mutational Analysis | 6 | 2017 | 2365 | 0.170 |
Why?
|
| Transcription Factor 4 | 1 | 2019 | 34 | 0.170 |
Why?
|
| Blood Alcohol Content | 1 | 2019 | 1 | 0.170 |
Why?
|
| Pathology | 1 | 2020 | 108 | 0.170 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2019 | 40 | 0.170 |
Why?
|
| Hematology | 1 | 2020 | 99 | 0.170 |
Why?
|
| Receptors, IgE | 1 | 2019 | 43 | 0.170 |
Why?
|
| Blotting, Southern | 2 | 2010 | 455 | 0.170 |
Why?
|
| Foreign Bodies | 1 | 2021 | 160 | 0.170 |
Why?
|
| Fatal Outcome | 5 | 2017 | 835 | 0.170 |
Why?
|
| Burns | 1 | 2020 | 126 | 0.170 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 1999 | 147 | 0.170 |
Why?
|
| Substance Withdrawal Syndrome | 2 | 2013 | 257 | 0.160 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2020 | 156 | 0.160 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2002 | 329 | 0.160 |
Why?
|
| Facial Neoplasms | 1 | 2019 | 77 | 0.160 |
Why?
|
| Remission Induction | 5 | 2021 | 3645 | 0.160 |
Why?
|
| Bone Marrow Examination | 2 | 2016 | 151 | 0.160 |
Why?
|
| B7-H1 Antigen | 3 | 2024 | 1075 | 0.160 |
Why?
|
| Endometriosis | 1 | 2022 | 235 | 0.160 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 1 | 2019 | 107 | 0.160 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 234 | 0.160 |
Why?
|
| Truth Disclosure | 2 | 2021 | 179 | 0.160 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2015 | 2270 | 0.160 |
Why?
|
| In Situ Hybridization | 4 | 2017 | 1061 | 0.160 |
Why?
|
| Vascular Neoplasms | 1 | 1999 | 113 | 0.160 |
Why?
|
| Immunoglobulin Variable Region | 1 | 1999 | 169 | 0.160 |
Why?
|
| Subcutaneous Tissue | 2 | 2017 | 58 | 0.160 |
Why?
|
| Ilium | 1 | 2018 | 54 | 0.160 |
Why?
|
| Endometrium | 1 | 2002 | 469 | 0.160 |
Why?
|
| Hypoxia | 2 | 2021 | 477 | 0.150 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 2018 | 86 | 0.150 |
Why?
|
| Herpesviridae Infections | 1 | 2019 | 181 | 0.150 |
Why?
|
| Trisomy | 2 | 2016 | 240 | 0.150 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2019 | 120 | 0.150 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2020 | 2472 | 0.150 |
Why?
|
| Abnormal Karyotype | 2 | 2020 | 101 | 0.150 |
Why?
|
| Acoustic Stimulation | 1 | 2018 | 120 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2021 | 9099 | 0.150 |
Why?
|
| Programmed Cell Death 1 Receptor | 2 | 2024 | 1091 | 0.150 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 809 | 0.150 |
Why?
|
| Interleukin-13 | 1 | 2018 | 130 | 0.150 |
Why?
|
| Patient Dropouts | 1 | 2018 | 84 | 0.150 |
Why?
|
| Heart Rate | 2 | 2013 | 761 | 0.150 |
Why?
|
| Pruritus | 1 | 2018 | 87 | 0.150 |
Why?
|
| Receptors, CCR4 | 1 | 2017 | 35 | 0.150 |
Why?
|
| Cell Differentiation | 3 | 2024 | 4195 | 0.150 |
Why?
|
| Herpes Zoster | 1 | 2017 | 53 | 0.150 |
Why?
|
| Ki-67 Antigen | 4 | 2023 | 685 | 0.150 |
Why?
|
| STAT3 Transcription Factor | 3 | 2019 | 1146 | 0.140 |
Why?
|
| Precursor Cells, B-Lymphoid | 1 | 2017 | 36 | 0.140 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2017 | 63 | 0.140 |
Why?
|
| Product Surveillance, Postmarketing | 1 | 2017 | 43 | 0.140 |
Why?
|
| Glycogen Storage Disease Type I | 1 | 2016 | 18 | 0.140 |
Why?
|
| History, 21st Century | 1 | 2019 | 422 | 0.140 |
Why?
|
| Ikaros Transcription Factor | 1 | 2017 | 53 | 0.140 |
Why?
|
| Gene Dosage | 2 | 2017 | 829 | 0.140 |
Why?
|
| Immunoblastic Lymphadenopathy | 1 | 2016 | 30 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2022 | 560 | 0.140 |
Why?
|
| Antigens, Neoplasm | 3 | 2017 | 1589 | 0.140 |
Why?
|
| Transplantation, Autologous | 2 | 2021 | 2048 | 0.140 |
Why?
|
| Physician's Role | 1 | 2019 | 232 | 0.140 |
Why?
|
| HIV Seropositivity | 2 | 2011 | 154 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2017 | 183 | 0.140 |
Why?
|
| Biopsy, Fine-Needle | 4 | 2016 | 698 | 0.140 |
Why?
|
| Cohort Studies | 10 | 2022 | 9491 | 0.140 |
Why?
|
| Antineoplastic Agents | 9 | 2018 | 14653 | 0.140 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2020 | 1534 | 0.140 |
Why?
|
| Global Health | 2 | 2019 | 691 | 0.140 |
Why?
|
| History, 20th Century | 1 | 2019 | 550 | 0.140 |
Why?
|
| Social Media | 1 | 2020 | 211 | 0.140 |
Why?
|
| Cytodiagnosis | 2 | 2010 | 228 | 0.140 |
Why?
|
| Motivation | 2 | 2018 | 512 | 0.140 |
Why?
|
| HLA Antigens | 1 | 2019 | 588 | 0.140 |
Why?
|
| Silicosis | 1 | 1996 | 6 | 0.140 |
Why?
|
| Apoptosis | 4 | 2016 | 7837 | 0.130 |
Why?
|
| Epidermis | 1 | 2017 | 200 | 0.130 |
Why?
|
| Transglutaminases | 1 | 2016 | 100 | 0.130 |
Why?
|
| S100 Proteins | 3 | 2020 | 190 | 0.130 |
Why?
|
| Feedback, Psychological | 1 | 2016 | 20 | 0.130 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2015 | 3978 | 0.130 |
Why?
|
| Antigens, CD20 | 2 | 2013 | 207 | 0.130 |
Why?
|
| Fibrosis | 4 | 2022 | 746 | 0.130 |
Why?
|
| Homozygote | 2 | 2022 | 771 | 0.130 |
Why?
|
| Databases, Factual | 3 | 2019 | 2287 | 0.130 |
Why?
|
| Primary Myelofibrosis | 2 | 2015 | 904 | 0.130 |
Why?
|
| Forkhead Transcription Factors | 2 | 2024 | 771 | 0.130 |
Why?
|
| Paraproteins | 1 | 2015 | 41 | 0.130 |
Why?
|
| Carcinoma, Papillary, Follicular | 1 | 1995 | 27 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2021 | 842 | 0.130 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2015 | 23 | 0.130 |
Why?
|
| Chromosome Disorders | 2 | 2015 | 425 | 0.130 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2016 | 80 | 0.130 |
Why?
|
| Parents | 1 | 2022 | 1066 | 0.130 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2009 | 5603 | 0.130 |
Why?
|
| Gene Expression Profiling | 7 | 2021 | 5186 | 0.130 |
Why?
|
| Health Behavior | 1 | 2020 | 602 | 0.130 |
Why?
|
| Immunologic Factors | 1 | 2019 | 668 | 0.130 |
Why?
|
| Cyclin-Dependent Kinase 5 | 1 | 2015 | 39 | 0.130 |
Why?
|
| Precancerous Conditions | 1 | 2002 | 1065 | 0.130 |
Why?
|
| Sarcoma, Myeloid | 1 | 2016 | 94 | 0.130 |
Why?
|
| Frontal Lobe | 1 | 1996 | 177 | 0.130 |
Why?
|
| Inclusion Bodies | 1 | 2015 | 91 | 0.130 |
Why?
|
| Skin Diseases, Viral | 1 | 2015 | 12 | 0.130 |
Why?
|
| Reward | 2 | 2022 | 174 | 0.120 |
Why?
|
| HTLV-I Infections | 1 | 2015 | 17 | 0.120 |
Why?
|
| Histiocytosis | 1 | 2015 | 56 | 0.120 |
Why?
|
| Antiviral Agents | 3 | 2017 | 1255 | 0.120 |
Why?
|
| Nuclear Proteins | 3 | 2014 | 3472 | 0.120 |
Why?
|
| RNA, Viral | 3 | 2016 | 729 | 0.120 |
Why?
|
| Survival Analysis | 9 | 2018 | 9325 | 0.120 |
Why?
|
| Multilevel Analysis | 1 | 2014 | 10 | 0.120 |
Why?
|
| TYK2 Kinase | 1 | 2014 | 9 | 0.120 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2020 | 1841 | 0.120 |
Why?
|
| Chromosome Inversion | 1 | 2016 | 197 | 0.120 |
Why?
|
| Immunoglobulin A | 1 | 2015 | 274 | 0.120 |
Why?
|
| Amyloid | 1 | 1995 | 94 | 0.120 |
Why?
|
| GTP-Binding Proteins | 1 | 2016 | 347 | 0.120 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 126 | 0.120 |
Why?
|
| Lymphoma, Primary Cutaneous Anaplastic Large Cell | 1 | 2014 | 9 | 0.120 |
Why?
|
| Eczema | 1 | 2015 | 34 | 0.120 |
Why?
|
| Thyroid Neoplasms | 2 | 2016 | 1884 | 0.120 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2017 | 531 | 0.120 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 220 | 0.120 |
Why?
|
| Blood Pressure | 2 | 2013 | 1603 | 0.120 |
Why?
|
| Platelet Count | 1 | 2015 | 491 | 0.120 |
Why?
|
| Immunoglobulin G | 2 | 2015 | 1140 | 0.120 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2021 | 1720 | 0.120 |
Why?
|
| Mastocytosis | 1 | 1994 | 21 | 0.120 |
Why?
|
| Neoplasms | 2 | 2015 | 15915 | 0.120 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 553 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2018 | 2085 | 0.120 |
Why?
|
| Texas | 6 | 2020 | 6435 | 0.120 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2012 | 190 | 0.120 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 1995 | 141 | 0.120 |
Why?
|
| Sudden Infant Death | 1 | 1994 | 34 | 0.120 |
Why?
|
| G1 Phase | 1 | 2015 | 306 | 0.120 |
Why?
|
| Neoplasms, Adnexal and Skin Appendage | 1 | 2014 | 65 | 0.120 |
Why?
|
| Signal Transduction | 6 | 2020 | 12222 | 0.120 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2015 | 300 | 0.120 |
Why?
|
| Janus Kinases | 1 | 2015 | 175 | 0.120 |
Why?
|
| Myxoma | 1 | 2014 | 68 | 0.120 |
Why?
|
| Sezary Syndrome | 1 | 2015 | 167 | 0.120 |
Why?
|
| Central Nervous System Depressants | 1 | 2013 | 30 | 0.110 |
Why?
|
| Wireless Technology | 1 | 2013 | 17 | 0.110 |
Why?
|
| Nose Neoplasms | 2 | 2013 | 236 | 0.110 |
Why?
|
| Analgesics, Opioid | 1 | 2024 | 1458 | 0.110 |
Why?
|
| Lewis X Antigen | 1 | 2013 | 41 | 0.110 |
Why?
|
| Periodicity | 1 | 2013 | 71 | 0.110 |
Why?
|
| Eye Neoplasms | 2 | 2014 | 257 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 319 | 0.110 |
Why?
|
| Leukemia, Myeloid | 1 | 2018 | 994 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 14 | 2 | 2012 | 288 | 0.110 |
Why?
|
| Odorants | 1 | 2013 | 80 | 0.110 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2013 | 17 | 0.110 |
Why?
|
| Fucosyltransferases | 1 | 2013 | 78 | 0.110 |
Why?
|
| Alleles | 3 | 2019 | 2599 | 0.110 |
Why?
|
| Genetic Predisposition to Disease | 6 | 2019 | 5750 | 0.110 |
Why?
|
| ras Proteins | 2 | 2015 | 802 | 0.110 |
Why?
|
| Bayes Theorem | 1 | 2018 | 1053 | 0.110 |
Why?
|
| Cell Line, Tumor | 10 | 2020 | 14875 | 0.110 |
Why?
|
| Drug Therapy | 1 | 2013 | 206 | 0.110 |
Why?
|
| Models, Psychological | 1 | 2014 | 179 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 64 | 0.110 |
Why?
|
| Immunoconjugates | 1 | 2016 | 314 | 0.110 |
Why?
|
| Composite Lymphoma | 1 | 2012 | 18 | 0.110 |
Why?
|
| Lymphocytes | 3 | 2022 | 1280 | 0.110 |
Why?
|
| Receptor, Notch2 | 1 | 2012 | 22 | 0.110 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2018 | 550 | 0.110 |
Why?
|
| Informed Consent | 1 | 2016 | 414 | 0.110 |
Why?
|
| Fibrocystic Breast Disease | 1 | 2012 | 46 | 0.100 |
Why?
|
| Genes, T-Cell Receptor delta | 1 | 2012 | 13 | 0.100 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2013 | 78 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 2 | 2023 | 126 | 0.100 |
Why?
|
| Activin Receptors, Type II | 1 | 2012 | 49 | 0.100 |
Why?
|
| Leukemia, Prolymphocytic, B-Cell | 1 | 2012 | 7 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2002 | 1389 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-pim-1 | 1 | 2012 | 45 | 0.100 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 504 | 0.100 |
Why?
|
| Animals | 12 | 2021 | 62807 | 0.100 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 1095 | 0.100 |
Why?
|
| Mediastinal Neoplasms | 1 | 2016 | 429 | 0.100 |
Why?
|
| Pheochromocytoma | 1 | 1995 | 313 | 0.100 |
Why?
|
| Heart Neoplasms | 1 | 2014 | 216 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2016 | 1568 | 0.100 |
Why?
|
| Spinal Cord | 1 | 1996 | 724 | 0.100 |
Why?
|
| Imatinib Mesylate | 1 | 2016 | 1690 | 0.100 |
Why?
|
| Receptors, Platelet-Derived Growth Factor | 1 | 2012 | 109 | 0.100 |
Why?
|
| Pilot Projects | 2 | 2016 | 2864 | 0.100 |
Why?
|
| Lymphoma, AIDS-Related | 1 | 2012 | 70 | 0.100 |
Why?
|
| Gene Rearrangement, B-Lymphocyte, Heavy Chain | 1 | 2011 | 41 | 0.100 |
Why?
|
| Exercise | 2 | 2021 | 1214 | 0.100 |
Why?
|
| Genes, Immunoglobulin Heavy Chain | 1 | 2011 | 37 | 0.100 |
Why?
|
| Tissue Donors | 1 | 2016 | 812 | 0.100 |
Why?
|
| Clone Cells | 1 | 2013 | 589 | 0.100 |
Why?
|
| Smoking | 2 | 2013 | 2538 | 0.100 |
Why?
|
| Watchful Waiting | 1 | 2013 | 292 | 0.100 |
Why?
|
| Karyotype | 2 | 2024 | 237 | 0.100 |
Why?
|
| Overweight | 1 | 2015 | 489 | 0.100 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2011 | 26 | 0.100 |
Why?
|
| Hepatitis C, Chronic | 1 | 2016 | 469 | 0.090 |
Why?
|
| Calbindin 2 | 1 | 2010 | 43 | 0.090 |
Why?
|
| Thalidomide | 1 | 2014 | 595 | 0.090 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2016 | 1613 | 0.090 |
Why?
|
| Tumor Microenvironment | 3 | 2021 | 3022 | 0.090 |
Why?
|
| S100 Calcium Binding Protein G | 1 | 2010 | 53 | 0.090 |
Why?
|
| Keratin-5 | 1 | 2010 | 57 | 0.090 |
Why?
|
| Keratin-6 | 1 | 2010 | 40 | 0.090 |
Why?
|
| Adenolymphoma | 1 | 2010 | 26 | 0.090 |
Why?
|
| Biopsy, Needle | 3 | 2017 | 1402 | 0.090 |
Why?
|
| Weight Loss | 1 | 2015 | 639 | 0.090 |
Why?
|
| Cell Proliferation | 6 | 2022 | 7300 | 0.090 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2015 | 895 | 0.090 |
Why?
|
| Prisoners | 1 | 2010 | 34 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2013 | 237 | 0.090 |
Why?
|
| Parotid Gland | 1 | 2010 | 116 | 0.090 |
Why?
|
| Juvenile Delinquency | 1 | 2010 | 27 | 0.090 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1995 | 532 | 0.090 |
Why?
|
| Imidazoles | 2 | 2016 | 1056 | 0.090 |
Why?
|
| Femur | 1 | 2011 | 162 | 0.090 |
Why?
|
| Neurocytoma | 1 | 2010 | 17 | 0.090 |
Why?
|
| Gender Identity | 1 | 2010 | 79 | 0.090 |
Why?
|
| Cytogenetics | 3 | 2016 | 152 | 0.090 |
Why?
|
| Transcription Factors | 2 | 2007 | 5505 | 0.090 |
Why?
|
| Autophagy | 1 | 2016 | 921 | 0.090 |
Why?
|
| Erythroid Cells | 1 | 2010 | 53 | 0.090 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2349 | 0.090 |
Why?
|
| Disruptive, Impulse Control, and Conduct Disorders | 1 | 2010 | 39 | 0.090 |
Why?
|
| Disease Susceptibility | 1 | 2012 | 545 | 0.090 |
Why?
|
| Anti-HIV Agents | 2 | 2003 | 353 | 0.090 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 5928 | 0.090 |
Why?
|
| Parotid Neoplasms | 1 | 2010 | 152 | 0.090 |
Why?
|
| Oligodendroglioma | 1 | 2010 | 106 | 0.080 |
Why?
|
| Receptors, Kainic Acid | 1 | 2009 | 5 | 0.080 |
Why?
|
| Serine | 1 | 2011 | 394 | 0.080 |
Why?
|
| Immunoenzyme Techniques | 3 | 2012 | 1209 | 0.080 |
Why?
|
| Pyridazines | 1 | 2012 | 319 | 0.080 |
Why?
|
| Peru | 3 | 2014 | 60 | 0.080 |
Why?
|
| Psychometrics | 3 | 2009 | 964 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2010 | 282 | 0.080 |
Why?
|
| Orbital Neoplasms | 1 | 2011 | 237 | 0.080 |
Why?
|
| Sensitivity and Specificity | 4 | 2024 | 5195 | 0.080 |
Why?
|
| Fingers | 1 | 2009 | 129 | 0.080 |
Why?
|
| Cell Cycle | 2 | 2012 | 2150 | 0.080 |
Why?
|
| Consensus | 2 | 2024 | 1116 | 0.080 |
Why?
|
| Repressor Proteins | 1 | 2016 | 1730 | 0.080 |
Why?
|
| Appendiceal Neoplasms | 1 | 2011 | 251 | 0.080 |
Why?
|
| Salvage Therapy | 1 | 2016 | 2119 | 0.080 |
Why?
|
| Oncogene Fusion | 2 | 2021 | 62 | 0.080 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2014 | 1259 | 0.080 |
Why?
|
| Paclitaxel | 1 | 2015 | 2099 | 0.080 |
Why?
|
| DNA Damage | 1 | 2016 | 1989 | 0.070 |
Why?
|
| Psychomotor Performance | 1 | 2009 | 239 | 0.070 |
Why?
|
| Cell Nucleus | 4 | 2011 | 1740 | 0.070 |
Why?
|
| Microscopy, Electron | 2 | 2000 | 734 | 0.070 |
Why?
|
| Neoplasm Grading | 1 | 2012 | 1827 | 0.070 |
Why?
|
| Social Support | 1 | 2010 | 590 | 0.070 |
Why?
|
| Genomics | 2 | 2015 | 2830 | 0.070 |
Why?
|
| Algorithms | 3 | 2017 | 3923 | 0.070 |
Why?
|
| Regulatory Factor X Transcription Factors | 1 | 2007 | 21 | 0.070 |
Why?
|
| Dasatinib | 1 | 2011 | 881 | 0.070 |
Why?
|
| Chorion | 1 | 2006 | 14 | 0.070 |
Why?
|
| Activating Transcription Factor 1 | 1 | 2007 | 21 | 0.070 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 461 | 0.070 |
Why?
|
| Reproducibility of Results | 5 | 2020 | 6210 | 0.070 |
Why?
|
| MicroRNAs | 2 | 2018 | 2912 | 0.070 |
Why?
|
| Chi-Square Distribution | 2 | 2008 | 1327 | 0.070 |
Why?
|
| Cell Count | 2 | 2022 | 524 | 0.070 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2007 | 85 | 0.070 |
Why?
|
| Tendons | 1 | 2007 | 75 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2007 | 92 | 0.070 |
Why?
|
| RNA-Binding Protein EWS | 1 | 2007 | 106 | 0.070 |
Why?
|
| Mastectomy | 3 | 2019 | 1557 | 0.070 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 1331 | 0.070 |
Why?
|
| Mice | 9 | 2021 | 36041 | 0.070 |
Why?
|
| Depressive Disorder | 1 | 2010 | 566 | 0.070 |
Why?
|
| Lymphatic Metastasis | 3 | 2019 | 4968 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 1177 | 0.070 |
Why?
|
| Phosphorylation | 4 | 2019 | 4984 | 0.070 |
Why?
|
| Research Design | 1 | 2013 | 1580 | 0.070 |
Why?
|
| DNA Copy Number Variations | 3 | 2020 | 1555 | 0.070 |
Why?
|
| Etoposide | 2 | 2019 | 905 | 0.070 |
Why?
|
| Carcinoma in Situ | 1 | 2009 | 496 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2006 | 223 | 0.060 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 2903 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2022 | 13400 | 0.060 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2012 | 4639 | 0.060 |
Why?
|
| Mice, SCID | 3 | 2017 | 1851 | 0.060 |
Why?
|
| Up-Regulation | 2 | 2024 | 2457 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 3 | 2019 | 4071 | 0.060 |
Why?
|
| Marijuana Use | 1 | 2024 | 11 | 0.060 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2008 | 906 | 0.060 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2004 | 56 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2017 | 2668 | 0.060 |
Why?
|
| United States | 5 | 2024 | 16050 | 0.060 |
Why?
|
| Mice, Inbred NOD | 2 | 2017 | 910 | 0.060 |
Why?
|
| Age of Onset | 3 | 2016 | 852 | 0.060 |
Why?
|
| Glia Maturation Factor | 1 | 2024 | 8 | 0.060 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 1741 | 0.060 |
Why?
|
| Polymorphism, Genetic | 1 | 2010 | 1559 | 0.060 |
Why?
|
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 1 | 2024 | 40 | 0.060 |
Why?
|
| Cameroon | 1 | 2003 | 15 | 0.060 |
Why?
|
| Gene Expression Regulation | 1 | 2015 | 4199 | 0.060 |
Why?
|
| Macrophages | 2 | 2020 | 1377 | 0.060 |
Why?
|
| Mental Disorders | 2 | 2009 | 884 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2017 | 7790 | 0.060 |
Why?
|
| International Cooperation | 2 | 2017 | 326 | 0.060 |
Why?
|
| HIV Seronegativity | 1 | 2003 | 35 | 0.060 |
Why?
|
| Salivary Glands, Minor | 1 | 2003 | 36 | 0.060 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 3 | 2010 | 219 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase Phosphatases | 1 | 2023 | 31 | 0.060 |
Why?
|
| Dual-Specificity Phosphatases | 1 | 2023 | 40 | 0.060 |
Why?
|
| Lymphocyte Activation | 2 | 2022 | 1728 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 2 | 2016 | 233 | 0.050 |
Why?
|
| STAT5 Transcription Factor | 2 | 2014 | 227 | 0.050 |
Why?
|
| Bartonella henselae | 1 | 2002 | 22 | 0.050 |
Why?
|
| Gestational Age | 1 | 2006 | 1153 | 0.050 |
Why?
|
| Diagnostic Errors | 2 | 2018 | 531 | 0.050 |
Why?
|
| Heart Valves | 1 | 2022 | 62 | 0.050 |
Why?
|
| Placenta | 1 | 2006 | 565 | 0.050 |
Why?
|
| Obesity | 1 | 2015 | 2958 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 4352 | 0.050 |
Why?
|
| Langerhans Cells | 1 | 2022 | 54 | 0.050 |
Why?
|
| CD27 Ligand | 1 | 2022 | 26 | 0.050 |
Why?
|
| Interferon Regulatory Factors | 1 | 2022 | 75 | 0.050 |
Why?
|
| Sclerosis | 1 | 2022 | 82 | 0.050 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2002 | 296 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2006 | 2337 | 0.050 |
Why?
|
| Exons | 2 | 2018 | 1388 | 0.050 |
Why?
|
| Neutrophils | 1 | 2006 | 876 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 179 | 0.050 |
Why?
|
| Tissue Array Analysis | 2 | 2015 | 760 | 0.050 |
Why?
|
| Cytokines | 2 | 2020 | 2840 | 0.050 |
Why?
|
| Medical Device Recalls | 1 | 2021 | 5 | 0.050 |
Why?
|
| Ulcer | 1 | 2022 | 80 | 0.050 |
Why?
|
| Janus Kinase Inhibitors | 1 | 2022 | 74 | 0.050 |
Why?
|
| Silicone Gels | 1 | 2021 | 19 | 0.050 |
Why?
|
| Molecular Targeted Therapy | 3 | 2019 | 2400 | 0.050 |
Why?
|
| Foreign-Body Reaction | 1 | 2021 | 32 | 0.050 |
Why?
|
| British Columbia | 1 | 2021 | 26 | 0.050 |
Why?
|
| Silicones | 1 | 2021 | 62 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2010 | 1296 | 0.050 |
Why?
|
| Africa, Western | 1 | 2000 | 16 | 0.050 |
Why?
|
| Peritoneum | 1 | 2022 | 150 | 0.050 |
Why?
|
| Autocrine Communication | 1 | 2001 | 93 | 0.050 |
Why?
|
| Regression Analysis | 1 | 2004 | 1588 | 0.050 |
Why?
|
| RNA-Binding Proteins | 1 | 2007 | 1025 | 0.050 |
Why?
|
| Erythroblasts | 2 | 2010 | 25 | 0.050 |
Why?
|
| Salivary Ducts | 1 | 2000 | 55 | 0.050 |
Why?
|
| Viral Load | 1 | 2002 | 482 | 0.050 |
Why?
|
| Videoconferencing | 1 | 2020 | 52 | 0.050 |
Why?
|
| Metaplasia | 1 | 2002 | 387 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2024 | 1650 | 0.040 |
Why?
|
| Equipment Failure | 1 | 2021 | 198 | 0.040 |
Why?
|
| Immunoglobulin kappa-Chains | 1 | 2020 | 73 | 0.040 |
Why?
|
| CD4 Antigens | 1 | 2000 | 171 | 0.040 |
Why?
|
| Hyperplasia | 1 | 2002 | 581 | 0.040 |
Why?
|
| CD8 Antigens | 1 | 2000 | 173 | 0.040 |
Why?
|
| Amino Acid Sequence | 2 | 2014 | 4635 | 0.040 |
Why?
|
| Inflammation | 3 | 2017 | 2533 | 0.040 |
Why?
|
| Bone Marrow Transplantation | 3 | 2017 | 1772 | 0.040 |
Why?
|
| Bendamustine Hydrochloride | 1 | 2020 | 122 | 0.040 |
Why?
|
| Gene Deletion | 2 | 2017 | 1487 | 0.040 |
Why?
|
| Protein Structure, Tertiary | 2 | 2014 | 1501 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2010 | 2974 | 0.040 |
Why?
|
| Cell Cycle Proteins | 3 | 2015 | 2129 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 626 | 0.040 |
Why?
|
| Rabbits | 1 | 2021 | 1077 | 0.040 |
Why?
|
| Therapies, Investigational | 1 | 2020 | 60 | 0.040 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2022 | 473 | 0.040 |
Why?
|
| Prevalence | 2 | 2014 | 3426 | 0.040 |
Why?
|
| Specialization | 1 | 2020 | 129 | 0.040 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 2020 | 220 | 0.040 |
Why?
|
| Exome | 2 | 2015 | 1252 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2020 | 224 | 0.040 |
Why?
|
| Molecular Sequence Data | 2 | 2014 | 6781 | 0.040 |
Why?
|
| Ovarian Neoplasms | 1 | 2015 | 4795 | 0.040 |
Why?
|
| Triage | 1 | 2021 | 258 | 0.040 |
Why?
|
| Genotyping Techniques | 1 | 2019 | 163 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 362 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2016 | 2035 | 0.040 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 5066 | 0.040 |
Why?
|
| Antibody Specificity | 1 | 1999 | 340 | 0.040 |
Why?
|
| Granulocytes | 1 | 1999 | 243 | 0.040 |
Why?
|
| Leukemia, Lymphoid | 1 | 1999 | 290 | 0.040 |
Why?
|
| Sex Factors | 3 | 2009 | 2206 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2001 | 593 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2020 | 296 | 0.040 |
Why?
|
| Proteasome Inhibitors | 1 | 2020 | 234 | 0.040 |
Why?
|
| Counseling | 1 | 2021 | 385 | 0.040 |
Why?
|
| Cross-Sectional Studies | 3 | 2016 | 4507 | 0.040 |
Why?
|
| Cicatrix | 1 | 2020 | 188 | 0.040 |
Why?
|
| Research | 1 | 2021 | 431 | 0.040 |
Why?
|
| Genotype | 1 | 2006 | 4265 | 0.040 |
Why?
|
| Genetic Variation | 1 | 2006 | 2156 | 0.040 |
Why?
|
| RNA Interference | 2 | 2014 | 1397 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2016 | 6986 | 0.040 |
Why?
|
| Information Dissemination | 1 | 2020 | 266 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 291 | 0.040 |
Why?
|
| Tissue Distribution | 1 | 1999 | 946 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 12012 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 1349 | 0.040 |
Why?
|
| Chromatin | 1 | 2023 | 1050 | 0.040 |
Why?
|
| Cytoreduction Surgical Procedures | 1 | 2022 | 508 | 0.040 |
Why?
|
| Syndrome | 1 | 2000 | 1405 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcr | 1 | 2017 | 69 | 0.040 |
Why?
|
| Adenine | 1 | 2020 | 669 | 0.040 |
Why?
|
| Incidence | 2 | 2018 | 5861 | 0.040 |
Why?
|
| Aminopterin | 1 | 2016 | 32 | 0.040 |
Why?
|
| Proportional Hazards Models | 2 | 2016 | 5118 | 0.040 |
Why?
|
| Interferon-gamma | 1 | 2001 | 1180 | 0.040 |
Why?
|
| Dermis | 1 | 2017 | 63 | 0.040 |
Why?
|
| Positive Regulatory Domain I-Binding Factor 1 | 1 | 2016 | 22 | 0.040 |
Why?
|
| Codon | 1 | 2017 | 262 | 0.040 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2020 | 609 | 0.030 |
Why?
|
| Risk | 1 | 2021 | 1950 | 0.030 |
Why?
|
| Epigenomics | 1 | 2018 | 268 | 0.030 |
Why?
|
| Pancytopenia | 1 | 2017 | 119 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2019 | 420 | 0.030 |
Why?
|
| Therapeutics | 1 | 2016 | 31 | 0.030 |
Why?
|
| Depsipeptides | 1 | 2016 | 77 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2019 | 1241 | 0.030 |
Why?
|
| Gene Rearrangement, T-Lymphocyte | 1 | 2016 | 67 | 0.030 |
Why?
|
| Infectious Mononucleosis | 1 | 2016 | 38 | 0.030 |
Why?
|
| Hepatomegaly | 1 | 2016 | 72 | 0.030 |
Why?
|
| Precision Medicine | 1 | 2024 | 1207 | 0.030 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 1102 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2021 | 746 | 0.030 |
Why?
|
| Isochromosomes | 1 | 2016 | 55 | 0.030 |
Why?
|
| Birefringence | 1 | 1995 | 12 | 0.030 |
Why?
|
| Leukemia, Megakaryoblastic, Acute | 1 | 1996 | 45 | 0.030 |
Why?
|
| Gene Fusion | 1 | 2017 | 214 | 0.030 |
Why?
|
| Laser Capture Microdissection | 1 | 2015 | 45 | 0.030 |
Why?
|
| Reticulin | 1 | 2015 | 22 | 0.030 |
Why?
|
| Phospholipase C gamma | 1 | 2015 | 59 | 0.030 |
Why?
|
| Paraproteinemias | 1 | 2015 | 59 | 0.030 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1996 | 245 | 0.030 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 2575 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2015 | 78 | 0.030 |
Why?
|
| Spleen | 1 | 2018 | 732 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2016 | 173 | 0.030 |
Why?
|
| Lymphoma, Extranodal NK-T-Cell | 1 | 2015 | 35 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 661 | 0.030 |
Why?
|
| Proteolysis | 1 | 2017 | 380 | 0.030 |
Why?
|
| RNA, Small Interfering | 2 | 2012 | 2218 | 0.030 |
Why?
|
| CD4-CD8 Ratio | 1 | 2015 | 57 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2017 | 265 | 0.030 |
Why?
|
| Jurkat Cells | 1 | 2015 | 320 | 0.030 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 399 | 0.030 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2015 | 109 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2019 | 809 | 0.030 |
Why?
|
| Phycoerythrin | 1 | 2014 | 4 | 0.030 |
Why?
|
| Hydroa Vacciniforme | 1 | 2014 | 6 | 0.030 |
Why?
|
| Interferons | 1 | 2016 | 301 | 0.030 |
Why?
|
| CD59 Antigens | 1 | 2014 | 11 | 0.030 |
Why?
|
| CD2 Antigens | 1 | 2014 | 30 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 13 | 1 | 2015 | 148 | 0.030 |
Why?
|
| Cytoplasm | 2 | 2010 | 718 | 0.030 |
Why?
|
| Tetraspanin 30 | 1 | 2014 | 14 | 0.030 |
Why?
|
| Piperidines | 1 | 2020 | 1091 | 0.030 |
Why?
|
| Fluorescein-5-isothiocyanate | 1 | 2014 | 52 | 0.030 |
Why?
|
| Receptors, Complement 3b | 1 | 2014 | 20 | 0.030 |
Why?
|
| Infant | 3 | 2017 | 13931 | 0.030 |
Why?
|
| Pimozide | 1 | 2014 | 8 | 0.030 |
Why?
|
| Neprilysin | 1 | 2014 | 64 | 0.030 |
Why?
|
| Immunoglobulins | 1 | 2015 | 289 | 0.030 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2015 | 114 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2014 | 46 | 0.030 |
Why?
|
| Cell Adhesion | 1 | 2017 | 1041 | 0.030 |
Why?
|
| Janus Kinase 3 | 1 | 2014 | 47 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2017 | 1076 | 0.030 |
Why?
|
| Virus Activation | 1 | 2016 | 236 | 0.030 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 2014 | 170 | 0.030 |
Why?
|
| Ambulatory Care | 2 | 2009 | 604 | 0.030 |
Why?
|
| Developed Countries | 1 | 2014 | 46 | 0.030 |
Why?
|
| Multigene Family | 1 | 2015 | 465 | 0.030 |
Why?
|
| Staining and Labeling | 1 | 1995 | 466 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 1994 | 156 | 0.030 |
Why?
|
| Histones | 1 | 2021 | 1514 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2014 | 162 | 0.030 |
Why?
|
| Lectins, C-Type | 1 | 2014 | 163 | 0.030 |
Why?
|
| CRISPR-Cas Systems | 1 | 2017 | 353 | 0.030 |
Why?
|
| Epithelial Cells | 1 | 2000 | 1891 | 0.030 |
Why?
|
| Janus Kinase 1 | 1 | 2014 | 125 | 0.030 |
Why?
|
| Pregnancy | 1 | 2006 | 8100 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2006 | 8602 | 0.030 |
Why?
|
| Family | 2 | 2008 | 778 | 0.030 |
Why?
|
| Lymphatic Diseases | 1 | 2013 | 130 | 0.030 |
Why?
|
| Review Literature as Topic | 1 | 2013 | 83 | 0.030 |
Why?
|
| B-Lymphocyte Subsets | 1 | 2013 | 51 | 0.030 |
Why?
|
| Recurrence | 1 | 2021 | 4886 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 4993 | 0.030 |
Why?
|
| Mass Spectrometry | 1 | 2015 | 726 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 47 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2018 | 2106 | 0.030 |
Why?
|
| Antigens, CD1 | 1 | 2012 | 48 | 0.030 |
Why?
|
| Cytarabine | 2 | 2015 | 2014 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2014 | 1093 | 0.030 |
Why?
|
| Sodium Chloride | 1 | 2012 | 163 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 2679 | 0.030 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2014 | 437 | 0.020 |
Why?
|
| Skin | 1 | 2017 | 1284 | 0.020 |
Why?
|
| Methotrexate | 1 | 2015 | 1032 | 0.020 |
Why?
|
| Cell Death | 1 | 2014 | 689 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2015 | 1832 | 0.020 |
Why?
|
| Mutation Rate | 1 | 2012 | 220 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2020 | 1544 | 0.020 |
Why?
|
| Polyethylene Glycols | 1 | 2015 | 642 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 73 | 0.020 |
Why?
|
| Brain | 1 | 2005 | 4252 | 0.020 |
Why?
|
| Splenectomy | 1 | 2012 | 168 | 0.020 |
Why?
|
| Bisexuality | 1 | 2011 | 21 | 0.020 |
Why?
|
| Tonsillitis | 1 | 2011 | 17 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2014 | 1074 | 0.020 |
Why?
|
| South America | 1 | 2011 | 54 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 1278 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2012 | 289 | 0.020 |
Why?
|
| Lymphadenitis | 1 | 2011 | 42 | 0.020 |
Why?
|
| Criminal Law | 1 | 2010 | 12 | 0.020 |
Why?
|
| Health Promotion | 1 | 2015 | 510 | 0.020 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1335 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2017 | 1158 | 0.020 |
Why?
|
| Prednisolone | 1 | 2011 | 133 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2012 | 626 | 0.020 |
Why?
|
| Chromosome Banding | 1 | 2010 | 280 | 0.020 |
Why?
|
| Cell Transformation, Viral | 1 | 2011 | 175 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2014 | 1470 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2015 | 1497 | 0.020 |
Why?
|
| Anemia, Refractory | 1 | 2010 | 40 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 309 | 0.020 |
Why?
|
| Appendectomy | 1 | 2011 | 130 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2011 | 502 | 0.020 |
Why?
|
| Cell Survival | 1 | 2016 | 3074 | 0.020 |
Why?
|
| Family Relations | 1 | 2010 | 88 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 5330 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2016 | 1136 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2002 | 3176 | 0.020 |
Why?
|
| Patient Selection | 1 | 2017 | 2043 | 0.020 |
Why?
|
| Transplantation, Homologous | 1 | 2016 | 3036 | 0.020 |
Why?
|
| Intraoperative Period | 1 | 2010 | 259 | 0.020 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 889 | 0.020 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 1575 | 0.020 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2009 | 23 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2015 | 1849 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 3539 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1756 | 0.020 |
Why?
|
| Tandem Repeat Sequences | 1 | 2010 | 203 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2004 | 4137 | 0.020 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 4399 | 0.020 |
Why?
|
| Pyridines | 1 | 2016 | 1312 | 0.020 |
Why?
|
| Computer Simulation | 1 | 2014 | 1572 | 0.020 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2011 | 372 | 0.020 |
Why?
|
| Blotting, Western | 1 | 2014 | 3646 | 0.020 |
Why?
|
| Radiopharmaceuticals | 1 | 2014 | 1338 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2012 | 1035 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 3651 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2010 | 420 | 0.020 |
Why?
|
| Arousal | 1 | 2008 | 129 | 0.020 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 1014 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2015 | 4359 | 0.020 |
Why?
|
| Minisatellite Repeats | 1 | 2007 | 66 | 0.020 |
Why?
|
| Pharmacogenetics | 1 | 2009 | 267 | 0.020 |
Why?
|
| Ependymoma | 1 | 2010 | 269 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 7929 | 0.020 |
Why?
|
| Base Sequence | 1 | 2014 | 5499 | 0.020 |
Why?
|
| Body Mass Index | 1 | 2015 | 2258 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2014 | 1409 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2008 | 233 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2012 | 1197 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2012 | 1230 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2014 | 5804 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 3928 | 0.020 |
Why?
|
| Melanoma | 1 | 2004 | 5592 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2020 | 5421 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2020 | 3545 | 0.020 |
Why?
|
| Computational Biology | 1 | 2012 | 1281 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 2496 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 3392 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2012 | 1482 | 0.020 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2011 | 624 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2008 | 1441 | 0.020 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2004 | 62 | 0.020 |
Why?
|
| Cocaine-Related Disorders | 1 | 2007 | 240 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 3417 | 0.010 |
Why?
|
| Genome, Human | 1 | 2012 | 1885 | 0.010 |
Why?
|
| MART-1 Antigen | 1 | 2004 | 113 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3853 | 0.010 |
Why?
|
| Patient Compliance | 1 | 2007 | 681 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2008 | 604 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2004 | 350 | 0.010 |
Why?
|
| Prostaglandins | 1 | 2001 | 84 | 0.010 |
Why?
|
| Interleukin-18 | 1 | 2001 | 91 | 0.010 |
Why?
|
| Macrophage Activation | 1 | 2001 | 151 | 0.010 |
Why?
|
| Logistic Models | 1 | 2008 | 3469 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 5104 | 0.010 |
Why?
|
| Comorbidity | 1 | 2007 | 2439 | 0.010 |
Why?
|
| Interleukin-1 | 1 | 2001 | 477 | 0.010 |
Why?
|
| Interleukin-12 | 1 | 2001 | 267 | 0.010 |
Why?
|
| Inflammation Mediators | 1 | 2001 | 408 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2001 | 482 | 0.010 |
Why?
|
| Adjuvants, Immunologic | 1 | 2001 | 692 | 0.010 |
Why?
|
| Nitric Oxide | 1 | 2001 | 666 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2001 | 2469 | 0.010 |
Why?
|
| Brazil | 1 | 1996 | 172 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2001 | 5840 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 7232 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 1996 | 1351 | 0.010 |
Why?
|